Optimizing LDL-C Lowering Therapy: Adherence, Guidelines, and Novel Treatments
EP. 1: Defining Treatment Goals Across the Cardiovascular Prevention Continuum
ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Tomasz Jurga, PharmD, BCPS, BCACP,Mary Cheeley, PharmD, BCPS, CLS, FNLA Panelists explore how treatment goals differ between primary and secondary cardiovascular prevention, emphasizing risk stratification, guideline application, and strategies to optimize long-term outcomes through individualized, multidisciplinary care.
EP. 2: Tailoring LDL-C Goals and Education Across Cardiovascular Risk Profiles
ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Tomasz Jurga, PharmD, BCPS, BCACP,Mary Cheeley, PharmD, BCPS, CLS, FNLA Panelists examine how LDL-C targets vary by cardiovascular risk level and highlights the role of pharmacists and multidisciplinary teams in delivering effective patient education to improve adherence and long-term outcomes.
EP. 3: Enhancing Risk Stratification with Coronary Calcium Scoring and Lp(a
ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Tomasz Jurga, PharmD, BCPS, BCACP,Mary Cheeley, PharmD, BCPS, CLS, FNLA Learn how CAC scans, PREVENT ASCVD scoring, and Lp(a) testing sharpen risk talks and guide statin choices in pharmacy practice.
EP. 4: Optimizing Post-ACS Management and Emerging LDL-C Lowering Strategies
ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Tomasz Jurga, PharmD, BCPS, BCACP,Mary Cheeley, PharmD, BCPS, CLS, FNLA Learn how CAC scores, PREVENT ASCVD, and Lp(a) reshape risk talks—help pharmacists personalize statins, targets, and follow‑up.
EP. 5: Addressing Statin Intolerance and Expanding Access to Non-Statin Therapies
ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Tomasz Jurga, PharmD, BCPS, BCACP,Mary Cheeley, PharmD, BCPS, CLS, FNLA Please paste the article text (or a link/excerpt). I’ll generate an SEO-friendly meta description (≤24 words, ≤150 characters) in present tense.
EP. 6: Improving Statin Adherence and Optimizing Combination Therapy
ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Tomasz Jurga, PharmD, BCPS, BCACP,Mary Cheeley, PharmD, BCPS, CLS, FNLA Learn how clinicians tailor add-on lipid therapies—PCSK9s, ezetimibe, bempedoic acid—using shared decisions, follow-up, and statin myths.
EP. 7: Guideline Updates and Optimizing Adherence in Post-ACS Lipid Management
ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Tomasz Jurga, PharmD, BCPS, BCACP,Mary Cheeley, PharmD, BCPS, CLS, FNLA Pharmacists speed cholesterol guideline adoption through patient education, prior auth support, and adherence fixes for
EP. 8: Integrating Novel Lipid-Lowering Therapies and Addressing Cardiovascular Care Costs
ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Tomasz Jurga, PharmD, BCPS, BCACP,Mary Cheeley, PharmD, BCPS, CLS, FNLA Pharmacists drive new cholesterol care: educate patients, tackle prior auth and cost barriers, and improve adherence to statins and
EP. 9: Facilitating Access to Non-Statin LDL-C Lowering Therapies
ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Tomasz Jurga, PharmD, BCPS, BCACP,Mary Cheeley, PharmD, BCPS, CLS, FNLA Paste the article text (or an excerpt), and I’ll generate a 150-character, 24-word max SEO meta description in present tense.
EP. 10: Expanding the Role of Pharmacists in Non-Statin LDL-C Therapy Utilization
ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Tomasz Jurga, PharmD, BCPS, BCACP,Mary Cheeley, PharmD, BCPS, CLS, FNLA Pharmacists unpack easier access to PCSK9 inhibitors and inclisiran—smart prior auth, Medicare Part B nuances, and foundation help that cuts costs.
EP. 11: The Evolving Role of Pharmacists in Cardiovascular Disease Management: Insights and Future Perspectives
ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Joseph J. Saseen, PharmD, BCPS, BCACP, CLS,Tomasz Jurga, PharmD, BCPS, BCACP,Mary Cheeley, PharmD, BCPS, CLS, FNLA Pharmacists step into cardiovascular prevention with patient education, statin protocols, and new prescribing training—if clinical work gets paid.
